Skip to main content

REVIEW article

Front. Oncol.
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1364345

Efficacy and safety of PD-1 Inhibitors plus anti-angiogenesis tyrosine kinase inhibitors with or without transarterial Chemo(Embolization) for unresectable hepatocellular carcinoma: A meta-analysis

Provisionally accepted
Yue Chen Yue Chen Tao Luo Tao Luo *Yu Li Yu Li Luyao Jia Luyao Jia Wenhao Cui Wenhao Cui Jukun Wang Jukun Wang Chunjing Bian Chunjing Bian
  • Xuanwu Hospital, Capital Medical University, Beijing, Beijing Municipality, China

The final, formatted version of the article will be published soon.

    The triple combination of programmed cell death protein-1 (PD-1) inhibitors plus anti-angiogenesis tyrosine kinase inhibitors(TKI) with or without transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) enhance the effect of treatment for unresectable hepatocellular carcinoma (uHCC). The present study compared the efficacy and safety of PD-1 plus TKI with or without transarterial Chemo(Embolization) for uHCC.The meta-analysis was conducted using data acquired from PubMed, EMBASE, the Cochrane Library, Ovid, Web of Science, and Clinical Trials.gov from the inception date to December 2023. All clinical outcomes of interest included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and adverse events (AEs). The hazard ratio (HR) and risk ratio (RR) with 95% confidence intervals (CI) were used to measure the pooled effect. And subgroup analysis was conducted to determine the specific patient population that benefited.The OS (HR=0.47; 95% CI: 0.39-0.56, P < 0.05), PFS (HR=0.52; 95% CI: 0.45-0.60, P < 0.05) and ORR (RR=1.94; 95% CI: 1.60-2.35, P<0.05) were significantly better in TACE/HAIC+TKI+PD-1(TACE/HAIC TP) group than TKI+PD-1(TP) group. The incidence of AEs was acceptable.The triple therapy of TACE/HAIC TP had better efficacy for uHCC than TP, with acceptable security.

    Keywords: Hepatic artery infusion chemotherapy, Transarterial chemoembolization, tyrosine kinase inhibitors, PD-1 inhibitors, unresectable hepatocellular carcinoma PROSPERO registration number: PROSPERO (CRD42023475953)

    Received: 10 May 2024; Accepted: 29 Jul 2024.

    Copyright: © 2024 Chen, Luo, Li, Jia, Cui, Wang and Bian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Tao Luo, Xuanwu Hospital, Capital Medical University, Beijing, 100053, Beijing Municipality, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.